U.S. Markets closed

Stereotaxis, Inc. (STXS)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.68+0.14 (+25.93%)
At close: 3:49PM EDT
People also watch
HNSNSPNCNUROSTAACRDC
  • R
    Robert
    Robert
    Looks like partner plans or a possible strategic alliance is in the works. Very early discussions but the truth remains that they are least "talking" to external partners. I'm still not sure what Mills was doing over there for all that time? Young CEO is on target, ambitious and clearly focused - just taking 2-3 years longer than anyone wants. Its still progress.
  • D
    David
    David
    Some good news guys. anyone knows how it is supposed to affect the company's sales?
  • w
    william
    william
    Stxs could possible make progress , the new Ceo stating that company Robotic technology could b leaverage in other Medical applications .will listen for any questions or updates in coming C.C. about exploiting Robotic technology ..It could be the game changer for what now appears to be dying company ..IMO
  • w
    williamm
    williamm
    Here's to at least two new systems sales in the most recent quarter and the beginnings of a new backlog. Need some momentum! Come on...papa needs shoes, baby needs clothes
  • m
    mike e
    mike e
    What is anyone’s opinion on this one? I owned it and sold around $1.00 a couple years ago. Sales aren’t great but they are selling a couple systems at least. The research side seems promising.
  • R
    Robert
    Robert
    Job well done over there . So well in fact they are all patting themselves on the back and handing out option awards. Pinch me.
  • D
    Don
    Don
    yes, slow growth vs no growth, still not as good as strong growth will good products. Looking to see if they introduce the upgrade in Europe, then bring it over to US. Will Wait to see if this new CEO is blowing smoke out his backside. He laid out how he expects the next 2 qtrs to go. If he can not keep his word, not worth owning.
  • M
    Maxmilian
    Maxmilian
    Guidance is safe....can only be improved....reason being that they have the two systems Fishel/Ceo was mentioning already in the backlog...booked and already paid for (prepaid) in Q4 (=Mills)...as such they will not be cash relevant this year....

    lets see what Fishel will add to that equation...
  • M
    Maxmilian
    Maxmilian
    Shareholder value is junk vs peers....reason, imo

    mgment does not care at all....when pos mills left he was happy to have achieved the "deleverage objective" after 3 years the public was not aware of (sse his remarks on q3 16)....the factual consequence

    1. zero insti in anymore/no interest
    2. zero funds in anymore/no interest
    3. zero analyst covering it/no interest

    in short...deengaging with the investment community worked fine for them....

    now, if new mgment changes that back to reeengaging the investment community it will be golden....however, it took mills more than 3 years to destruct the company...as such it will take time to recover because it is a credibility issue in the first place...

    at least there is guidance (which needs to be upped on a regular basis)...also there is the automation path specified and the stop VT clinical...seems easy
  • D
    Don
    Don
    OK , Give the new CEO a brownie point for doing one thing he said he would do. Now how will this help them financially moving forward
  • W
    Whognu
    Whognu
    Where is the Masimo effect? They throw in $24 million and put new CEO in. When do they get this thing rolling?
  • R
    Robert
    Robert
    Growing slow on purpose.

    Been thinking about this lately. Consider the fact that they have no competitors. Why? Because the market for robotic ablations is slow, stale and fading. But then think about the other way - if they had something useful then everyone would want one, of course they could not make them fast enough, and then larger competitors would enter the space.

    My theory is that they have planned this all along and still want another 2-3 years to exist in the dark. Then, one day, they are going to flip the switch and let the cat out of the bag about all they had been planning for all these years.

    Its going to be dead money for quite some time unless boy wonder decides he wants to share the news a little bit.

    Also anyone know what happened to Mills? I could see that guy retiring at a golf course or something, telling old jokes at the bar and then maybe getting drunk on happy hour?
  • s
    steve
    steve
    What caused the sudden drop shortly before trading closed ?
  • D
    David
    David
    hey, i am considering buying some shares of STXS - looks like the guys from Dafna Capital took over... they are professional investors. any thoughts?
  • W
    Whognu
    Whognu
    Any discussion on the latest earning call. Sounds like they want to do well and that they believe they have the right product. The call was great until questions were asked and then my optimism was drowned by lousy answers to simple, basic questions. What a shame.
  • R
    Robert
    Robert
    Just listened to call. Did they say they have 25 sales reps worldwide and have visibility on ONE new system sale for all of 2017? Should it be me or someone else who calls them and lets them know they don't need a sales force? They need farmers and account managers to only act on current sites.
  • P
    Pharmaherooooooo
    Pharmaherooooooo

    BIG DEAL TO ACQUIRE UP TO 9 MARKETED PRODUCTS IMMINENT = 2000%++ UPSIDE POTENTIAL !!!
    AQSZF (MC $11 M) is close to profitability and to file 3 NDA and the whole company is valued at ridiculous $11 Million ,this unknown stock is definitely one of the cheapest Biotech in the sector .Stock should be at minimum $2+ right now .

    Market Cap :US$ 11 Million
    Cash $4.1 Million << enough untill mid 2018
    Price 0.18

    MUST WATCH to realize the MONSTER POTENTIAL HERE
    https://www.youtube.com/watch?v=jV00WmYBtv4

    Presentation
    http://www.aequuspharma.ca/Investors/AQS%20investor%20November%202016_web.pdf

    Operational profitability estimated in 2017

    File for CDN approval of Topiramate XR in 1H 2017

    File for CDN approval of Oxcarbazepine XR in 1H 2017

    Additional Product Deals in 2017

    Partnership for AQS1301 in 2017

    Two products launches to date (Tacrolimus IR and Vistitan™)

    3 long-acting, transdermal programs in development, on track to file NDA in 2018

    Aequus Pharmaceuticals
    Aequus has an expanding product pipeline of drugs in Canada. Revenues and cash flows are increasing and products produce a 50% margin, Edward Karr, Managing ...
    www.youtube.com
  • R
    Robert
    Robert
    Interesting momentum out there on renal denervations. Looking through the ongoing work (Symplicity Spyral, RADIANCE-HTN (NCT02649426) and REINFORCE (NCT02392351, n=100)) lots of new interest out there. What is encouraging is that back in 2011 Petr Neuzil, MD, PhD, Head of Cardiology and Director of the Cardiac Arrhythmia Service at the Na Homolce Hospital in Prague, Czech Republic used a Niobe to get this done and had 100% accuracy of ablations whereas the struggle even with say symplicity is that you have to "hope and pray" you are in the right area.
  • R
    Robert
    Robert
    Double down on VT where they know <5% of all cases really need it. When are they going to start using this machine in other areas and actually think about growing their sweet spot? Cardio alone isn't going to cut it.
  • J
    Jack
    Jack
    sick management these people only want pay check and bonus that all not really worried about the company and share holder fxxk that CEO